Can we make stroke during cardiac surgery a never event?

Michael Mack, MD

Stroke has been and continues to be the Achilles heel of cardiac surgery. Periprocedural neurologic events during cardiac surgery remain prevalent, with stroke reported in 2.0% to 4.6% of patients undergoing cardiac surgery and increasing to at least 12.8% in octogenarians.1-3 The fear of stroke or other adverse neurologic outcomes, including so-called pump head, is a deterrent for patients to undergo the otherwise successful, life-saving operations that we perform. The interpretation of the SYNTAX trial “that with coronary artery bypass grafting (CABG) the patient is trading a 3 times higher risk of stroke (2.2% vs 0.6%; \( P = .003 \)) for an increased risk of repeat revascularization with percutaneous coronary intervention (PCI)”4 is a frequent refrain heard throughout the interventional cardiology community. This concern about comparative periprocedural stroke risk of CABG and PCI is further substantiated by a comparison of stroke rates in approximately 190,000 Medicare patients by Edwards and colleagues.5 The 30-day stroke rate for CABG was 4 times higher than with PCI (1.55% vs 0.37%). Furthermore, the incidence of stroke after CABG reported in the Society of Thoracic Surgeons (STS) Adult Cardiac Surgery Database has not decreased over the past 10 years. This raises the question: Can we lower the risk of stroke during CABG to that of PCI or less?

This question has been asked many times over the past few decades, but a positive answer has proven elusive with no clear benefits demonstrated with various interventions and modifications of surgical technique. There are many reasons why it has been difficult to determine the benefits of different options to decrease stroke risk. There are multiple factors implicated in causing stroke during and after CABG, including preexisting carotid and cerebral vascular disease, use of cardiopulmonary bypass, perfusion pressure during the procedure, manipulation of the ascending aorta, and postoperative atrial fibrillation being the most likely culprits. With a relatively low incidence of stroke, powering randomized trials to demonstrate benefit is prohibitive and registry-based assessment is plagued by inconsistency in definitions, underreporting, selection bias, and treatment variability.

The avoidance of cardiopulmonary bypass with off-pump CABG was 1 way proposed to reduce the risk of stroke. However, the role of off-pump CABG in reducing that risk has been mixed at best with recent, randomized trials not demonstrating any decrease in stroke.\(^6\)\(^7\) Moss and colleagues\(^8\) shed some significant light on the causation and prevention of stroke during CABG in their recently published study. Moss and colleagues\(^8\) analyzed the outcomes of 12,079 isolated CABG procedures over 11 years. Aortic manipulation was completely avoided by using in situ internal thoracic arteries for inflow in 1552 patients (12.9%), a clampless facilitating device was used for proximal anastomoses in 1548 patients (12.8%), and aortic clamping was used in 8979 patients (74.3%). The overall incidence of stroke was 1.4%, with an incidence of 0.6% in the no aortic touch group, 1.2% in the clampless facilitating device group, and 1.5% in the clamp group (\( P < .01 \) for no touch vs clamp). As stated by Hammon\(^9\) in the accompanying editorial comment, despite a heavier burden of atherosclerotic disease in the ascending aorta, a no touch aortic technique can lower the perioperative stroke risk to that of PCI.

Using the same no aortic touch technique, Prapas and colleagues (personal communication, November 2014) using bilateral internal thoracic artery grafts off-pump in 3723 consecutive patients from 2001 to 2014, demonstrated that the incidence of stroke during CABG was a virtually identical: 0.35%.

So what is the takeaway message? From this and other evidence in the literature, I propose:

1. All patients undergoing CABG should also have epi-aortic ultrasound to assess the ascending aorta for atherosclerotic disease.\(^10\)
2. Avoiding any manipulation of the ascending aorta best minimizes the risk of stroke; this is done optimally by off-pump coronary bypass and use of in situ bilateral internal thoracic arteries.\(^8\)
3. If a graft needs to be placed on the ascending aorta, a clampless technique for performing the proximal anastomosis(es) should be used.\(^8\)
4. If cardiopulmonary bypass is used, a single complete crossclamp should be used rather than partial clamping.\(^11\)
Although these principles apply to CABG, the risk of stroke during aortic valve replacement is a totally separate and perhaps even larger issue. In a study by Messé and colleagues, the Determining Neurologic Outcomes from Valve Operations Study, they determined that the clinical incidence of stroke after surgical aortic valve replacement was 17%; the highest yet reported in the literature. The reason for such a high stroke rate was that a neurologist examined all patients preoperatively and performed serial postoperative neurologic exams. In the same group of patients, the incidence of stroke reported to the STS database was 7%. Furthermore, 54% of the patients who did not experience a clinical stroke had evidence of cerebral emboli by diffusion-weighted magnetic resonance imaging (DWI). So it is evident that the harder you look, the more you find. With careful preoperative and serial postoperative neurologic assessment by a neurologist and routine use of DWI, the incidence of brain injury after surgical aortic valve replacement is much higher than reported in the STS database and previously reported in the literature. The significance of subclinical lesions detected by imaging is not known, but there is increasing evidence that cerebral embolic burden is associated with late neurocognitive decline.

To emphasize the importance of lesions detected on DWI without clear clinical findings, the new American Heart Association/American Stroke Association statement has modified the definition currently used in the STS database and most recent clinical trials. Stroke is now defined as “a central nervous system infarction defined as brain, spinal cord, or retinal cell death attributable to ischemia, based on neuropathological, neuroimaging, and/or clinical evidence of permanent injury.” In other words, lesions found on DWI count as strokes even in the absence of obvious clinical findings. As this new definition is more widely adopted and standardized, the reported incidence of brain injury during cardiac surgery can be expected to increase.

The importance of brain injury during surgical aortic valve replacement and transcatheter aortic valve replacement has stimulated intense interest in the field of cerebral embolic protection. Cerebral protection devices fall into 2 broad categories: embolic capture and embolic deflection. A recent study using a capture device for emboli during transcatheter aortic valve replacement, the Montage Cerebral Protection System (Claret Medical, Santa Rosa, Calif) has been shown to decrease embolic load demonstrated by DWI to protected areas of the brain by 60% and decrease the incidence of clinical ataxia from 24% to 9%. A small study of 15 patients undergoing transthoracic aortic valve replacement with a deflection device, the Embrella (Edwards Lifesciences, Irvine, Calif), showed a decrease in cerebral embolic lesion volume but not compared with historical controls. There are currently 2 devices with the potential to decrease cerebral emboli after surgical aortic valve replacement. The Embol-X device (Edwards Lifesciences, Irvine, Calif) is a filter designed to capture emboli that is placed in the ascending aorta during placement and removal of the aortic crossclamp. The safety and efficacy of this device will be studied in a randomized trial of 330 patients in the Cardiothoracic Surgery Network sponsored by the National Heart, Lung, and Blood Institute. A second device with a totally different concept, the Cardiogard Cannula, (Cardiogard Medical, Ltd, Or Yehuda, Israel) has a suction side port attached to the aortic cannula that creates a vortex at the cannula tip thereby removing the majority of both solid and gaseous emboli. It has demonstrated efficacy in a small randomized trial and will likely start randomized trials in the United States soon.

The importance of preventing adverse neurologic outcomes after surgical and catheter-based procedures is highlighted by the fact that preliminary discussions have occurred between multiple stakeholders in the field, including the National Heart, Lung, and Blood Institute-sponsored Cardiothoracic Surgery Network and the STS/American College of Cardiology Transcatheter Valve Therapy registry to set up a network of study sites with expertise in neurologic outcomes assessment capable of performing randomized trials using a registry infrastructure.

The issue of stroke during cardiac surgery and transcatheter aortic valve replacement cannot be ignored. The consequences of brain injury are both acute and long-term. As we become more informed as to how to detect injury, including careful examinations by neurologists and broader use of DWI, the magnitude of the problem will become even more apparent. It behooves us to adopt the techniques for CABG that have demonstrated benefit; that is, “Don’t touch that aorta.” The light in the field of transthoracic aortic valve replacement is now focused on mechanisms to prevent brain injury by cerebral embolic protection. We need the same focus with surgical aortic valve replacement to minimize this risk. We can serve our patients better by making a concerted effort to make stroke and brain injury never events during all cardiac operations.

References


